GLP-1 RAs are used in diabetic patients but liraglutide is also approved for the treatment of obesity; interestingly, liraglutide has been shown to improve lipid and lipoprotein profile, and sdLDL, in a rigorous randomized, placebo-controlled, cross-over, double-blind study on patients with obesity, regardless the presence of diabetes [63]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.